摘要
目的评价TRA对HER2阳性BC患者肝毒性和胃肠道不良反应的风险。方法检索PubMed、Cochrane Library、Embase、Web of Science、CNKI及万方数据库,收集TRA治疗HER2阳性BC患者肝毒性和胃肠道不良反应的RCT研究。采用RevMan5.3软件进行Meta分析。结果共纳入23项RCT,结果显示,ALT升高[RR=1.90,95%CI(1.52,2.38),P<0.01]、AST升高[RR=2.18,95%CI(1.79,2.65),P<0.01]发生率显著高于对照组,而恶心、呕吐发生率与对照组相比差异无统计学意义。结论在TRA治疗HER2阳性BC患者后,肝毒性发生率明显升高,胃肠道不良反应发生率无显著差异。因此,在临床上需密切监测肝功能并注意胃肠道不良反应。
Objective To evaluate the risk of hepatic toxicity and gastrointestinal adverse reactions in HER2 positive BC patients treated with TRA.Methods PubMed,Cochrane Library,Embase,Web of Science,CNKI and Wanfang database were searched for RCT studies about the hepatotoxicity and gastrointestinal adverse reactions with TRA treatment in HER2 positive BC patients.Meta-analysis was performed by RevMan 5.3 software.Results A total of 23 studies were included,and meta-analysis showed that the incidence of elevated ALT(RR=1.90,95%CI(1.52,2.38),P<0.01)and AST(RR=2.18,95%CI(1.79,2.65),P<0.01)were significantly higher than those in control group,and there was no statistically significant in the difference of incidence of diarrhea,nausea,and vomiting which compared with control group.Conclusions After TRA treatment in HER2 positive BC patients,the incidence of hepatotoxicity significantly increase,and there is no significant difference in the incidence of gastrointestinal adverse reactions.Therefore,it is necessary to closely monitor liver function and pay attention to gastrointestinal reactions in clinic.
作者
李亚佳
刘玲艳
杨平雄
黄艳华
何功浩
LI Yajia;LIU Lingyan;YANG Pingxiong;HUANG Yanhua;HE Gonghao(School of Pharmacy,Dali University,Dali Yunnan 671000,China;Department of Clinical Pharmacy,920th Hospital of PLA Joint Logistics Support Force,Kunming Yunnan 650032,China)
出处
《云南医药》
CAS
2023年第4期58-65,共8页
Medicine and Pharmacy of Yunnan
基金
云南省应用基础研究计划(昆医联合专项)面上项目(202101AY070001-300)
联勤保障部队第九二〇医院科技计划项目(2020YGB11)。
